ArticleAsian Pacific journal of cancer prevention : APJCP2025
Anti-Tumor and Apoptotic Potential of 4-hydroxy-2-Methylbenzothiazole on MDA-MB-231 Cell Line.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinoma is a prevalent and life-threatening disease in women, requiring early detection for effective treatment. Its development is influenced by genetic, hormonal, and lifestyle factors. The MDA-MB-231 cell line is widely used to investigate breast cancer biology and therapy. 4-Hydroxy-2-methylbenzothiazole has demonstrated promising cellular effects, including antioxidant, anti-proliferative, and pro-apoptotic activities. The present research assessed the apoptotic, anti-proliferative, and antioxidant effects of 4-hydroxy-2-methylbenzothiazole in MDA-MB-231 cells. The study was categorized into an untreated group and three experimental groups treated with different doses of 4-hydroxy-2-methylbenzothiazole. Cell viability was evaluated using MTT, crystal violet, and trypan blue assays. Angiogenesis and apoptosis were measured by ELISA of VEGF and p53, while antioxidants were assessed by GSH and SOD levels. A 50 µg/ml dose of 4-hydroxy-2-methylbenzothiazole showed significant effects compared to the control groups. MTT, crystal violet, and trypan blue assays revealed that 4-hydroxy-2-methylbenzothiazole reduced the viability of MDA-MB-231 cells and promoted cell death. ELISA results further demonstrated a decrease in angiogenic potential, elevated p53 levels, and a reduction in SOD and GSH antioxidant levels. Additionally, scratch assay and DAPI/PI staining confirmed apoptosis. These findings suggest that 4-hydroxy-2-methylbenzothiazole exerts significant apoptotic and anti-proliferative effects on MDA-MB-231 breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.